discontinue sulfonylurea when starting glp-1 receptor agonist agonists for individualized treatment of type 2 diabetes mellitus Safety and Tolerability of Glucagon-Like

This result may be due to dose escalation between the switch and follow-up: the label for injectable semaglutide recommends titration from 0.25 to 0.5 mg 4 weeks after treatment initiation, with the possibility of further titration to 1 mg after another 4 weeks [4]

If you then eat a huge meal, it spikes sharply

A systematic review and meta-analysis published in eClinicalMedicine reported pooled mean weight regain of 5.63 kg and 5.81 percent of body weight

(Tell me in the comments #ObesityMedicine #GLP1 #WeightManagement #FDAApproval #ClinicalPharmacy #MedicationAccess #PublicHealth #HealthEquity #ThePublicHealthPharmacist To view or add a comment, sign in The FDA has granted expedited approval to Eli Lilly's new weight-loss pill, orforglipron (Foundayo), marking it as the second daily oral GLP-1 medication for obesity

Similarly, an analysis utilizing the UK Clinical Practice Research Datalink (CPRD) revealed that GLP-1 RAs were linked to an increased incidence of intestinal obstruction requiring hospitalization, compared to sodium-glucose cotransporter-2 (SGLT-2) inhibitors (1.9 vs

placebo when combined with a moderate-intensity lifestyle intervention (Supplementary Table 1)